Xilio Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Xilio Therapeutics, Inc. (XLO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 389.63 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-12
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 362.64K shares, a 42.36% increase year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 26.99K shares, a 91.57% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was -633.92K shares, a 480.76% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 111.13K shares, a 60.86% decline year-over-year.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 52.12K shares, a 96.92% decline from fiscal 2024.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.69M shares, a 36.60% increase from fiscal 2023.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.24M shares, a 42.49% increase from fiscal 2022.
- Xilio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 870.61K shares, a 88.87% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 362.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 389.63K shares 10-Q · filed 2026-08-12 | -244.29K shares derived: sum of 3 quarters · filed 2026-08-12 | -133.17K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 26.99K shares 10-Q · filed 2026-05-12 | -606.93K shares derived: sum of 2 quarters · filed 2026-05-12 | -495.81K shares derived: sum of 3 quarters · filed 2026-05-12 | -241.08K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | -633.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -522.79K shares derived: sum of 2 quarters · filed 2026-03-23 | -268.06K shares derived: sum of 3 quarters · filed 2026-03-23 | 52.12K shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 111.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 365.86K shares derived: sum of 2 quarters · filed 2025-11-13 | 686.04K shares 10-Q · filed 2025-11-13 | 852.52K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 254.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 574.91K shares 10-Q · filed 2025-08-14 | 741.40K shares derived: sum of 3 quarters · filed 2025-08-14 | 1.03M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 320.18K shares 10-Q · filed 2025-05-08 | 486.67K shares derived: sum of 2 quarters · filed 2025-05-08 | 770.59K shares derived: sum of 3 quarters · filed 2025-05-08 | 1.52M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 166.49K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 450.41K shares derived: sum of 2 quarters · filed 2025-03-11 | 1.20M shares derived: sum of 3 quarters · filed 2025-03-11 | 1.69M shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 283.92K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 1.03M shares derived: sum of 2 quarters · filed 2024-11-07 | 1.53M shares 10-Q · filed 2024-11-07 | 1.90M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 746.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.24M shares 10-Q · filed 2024-08-08 | 1.61M shares derived: sum of 3 quarters · filed 2024-08-08 | 1.82M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 498.11K shares 10-Q · filed 2024-05-14 | 865.80K shares derived: sum of 2 quarters · filed 2024-05-14 | 1.08M shares derived: sum of 3 quarters · filed 2024-05-14 | 1.34M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 367.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | 578.36K shares derived: sum of 2 quarters · filed 2024-04-01 | 837.25K shares derived: sum of 3 quarters · filed 2024-04-01 | 1.24M shares 10-K · filed 2024-04-01 |
| 2023-09-30 | 210.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 469.57K shares derived: sum of 2 quarters · filed 2023-11-09 | 872.87K shares 10-Q · filed 2023-11-09 | 1.05M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 258.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 662.19K shares 10-Q · filed 2023-08-14 | 835.35K shares derived: sum of 3 quarters · filed 2023-08-14 | 1.27M shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 403.30K shares 10-Q · filed 2023-05-09 | 576.46K shares derived: sum of 2 quarters · filed 2023-05-09 | 1.01M shares derived: sum of 3 quarters · filed 2023-05-09 | 1.26M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 173.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 603.01K shares derived: sum of 2 quarters · filed 2023-03-02 | 858.36K shares derived: sum of 3 quarters · filed 2023-03-02 | 870.61K shares 10-K · filed 2023-03-02 |
| 2022-09-30 | 429.86K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 685.21K shares derived: sum of 2 quarters · filed 2022-11-09 | 697.46K shares 10-Q · filed 2022-11-09 | 753.38K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 255.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 267.60K shares 10-Q · filed 2022-08-09 | 323.52K shares derived: sum of 3 quarters · filed 2022-08-09 | |
| 2022-03-31 | 12.25K shares 10-Q · filed 2022-05-12 | 68.17K shares derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2021-12-31 | 55.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 460.97K shares 10-K · filed 2022-03-01 | ||
| 2021-09-30 | 405.05K shares 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |